VoiceMed Raising Seed After AsthmaClimb Launch

VoiceMed is currently fundraising €300k. Pictured is Arianna Arienzo, VoiceMed CEO. (Photo © VoiceMed)


Luxembourg healthtech firm VoiceMed is currently fundraising €300k, a seed round that is expected to close in March 2023. 

The finance will boost the device’s market fit by generating more user feedback, while also supporting a three-month clinical study to generate data for its planned digital respirometer. 

VoiceMed leverages biomarkers in respiratory diseases and aims to improve access to healthcare through digital applications. 

Founded during a covid-related hackathon, at the end of December 2022 it launched its first asthma management medical device AsthmaClimb in the UK. 

The coaching app offers breathing exercises and feedback for adults who have asthma, through a gamified process spanning seven programmes named after the highest mountains on each continent. 

“The higher you go, the more difficult it is to complete the programme, but the better your asthma management will be,” VoiceMed CEO Arianna Arienzo explained. 

The app, which is aimed at adults and has the official C safety mark for UK distribution, was developed following wide scale testing with asthma patients. 

It responds to a gap in the market when it comes to accessing information about breathing exercises designed specifically for asthma patients. At the same time, the monitoring side of the app helps patients better understand the disease and what exacerbates it so they can mitigate against a future asthma attack. 

After closing this first round, VoiceMed, currently a team of eight, will begin raising for a second funding round of €700K to scale its products in the market.

Total
0
Shares
Related Posts
Total
0
Share